Opinion|Videos|August 18, 2023
The Evolving Treatment Paradigm for Plaque Psoriasis
Author(s)Alexandra K. Golant, MD , Mona Shahriari, MD, FAAD
Experts in dermatology comment on the impact of both roflumilast and tapinarof on the treatment of plaque psoriasis.
Advertisement
Episodes in this series
Advertisement
Related to this article
Takeda’s investigational oral TYK2 inhibitor is supported by phase 3 LATITUDE data demonstrating significant skin clearance versus placebo and apremilast.
In a 52-week open-label trial, tildrakizumab-asmn (Ilumya) reduced a mortality-linked DNA methylation clock by up to 0.5 years while clearing psoriasis symptoms.
Post hoc RESOLVE analysis shows that patients weighing at least 100 kg experience slower clinical response rates to brodalumab than those under 100 kg, establishing body weight over BMI as a key predictor of treatment timing.
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Topical Solution Shows Long-Term Promise for Male Pattern Hair Loss
2
Neutrogena Launches New Sunscreens With Newly Permitted UV Filter Bemotrizinol
3
Dersimelagon NDA Accepted by FDA with Priority Review for EPP, XLP
4
Maui Derm NP+PA Fall 2026 Day 2: GLP-1s, Inflammatory Disease, and Diagnostic Challenges
5